Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.
复制标题
DOI：
10.1001/archinternmed.2010.319
复制
发表时间：
2010-09-27
影响因子：
--
通讯作者：
Schaeffer, Anthony J.
中科院分区：
文献类型：
--
作者：
Pontari, Michel A.;Krieger, John N.;Litwin, Mark S.;White, Paige C.;Anderson, Rodney U.;McNaughton-Collins, Mary;Nickel, J. Curtis;Shoskes, Daniel A.;Alexander, Richard B.;O'Leary, Michael;Zeitlin, Scott;Chuai, Shannon;Landis, J. Richard;Cen, Liyi;Propert, Kathleen J.;Kusek, John W.;Nyberg, Leroy M., Jr.;Schaeffer, Anthony J.
Evidence suggests that the urogenital pain of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) may be neuropathic. This randomized, double-blind, placebo-controlled trial was conducted across 10 tertiary care centers in North America to determine whether pregabalin, which has been proved effective in other chronic pain syndromes, is effective in reducing CP/CPPS symptoms. In 2006–2007, 324 men with pelvic pain for at least 3 of the previous 6 months were enrolled in this study. Men were randomly assigned to receive pregabalin or placebo in a 2:1 ratio and were treated for 6 weeks. Pregabalin dosage was increased from 150 to 600 mg/d during the first 4 weeks. The primary outcome was a 6-point decrease in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score. Multiple secondary outcomes were assessed. Of 218 men assigned to receive pregabalin, 103 (47.2%) reported at least a 6-point decrease in the NIHCPSI total score at 6 weeks compared with 35.8% (38 of 106 men) assigned to receive placebo (P = .07, exact Mantel-Haenszel test, adjusting for clinical sites). Compared with the placebo group, men assigned to receive pregabalin experienced reductions in the NIH-CPSI total score and sub-scores (P < .05), a higher Global Response Assessment response rate (31.2% and 18.9%; P = .02), and improvement in total McGill Pain Questionnaire score (P = .01). Results for the other outcomes did not differ between groups. Pregabalin therapy for 6 weeks was not superior to placebo use in the rate of a 6-point decrease (improvement) in the NIH-CPSI total score in men with CP/CPPS. clinicaltrials.gov Identifier: NCT00371033
登录
查看更多内容
影响因子：
2.1
作者：
Propert, KJ;Mayer, RD;Kusek, JW
通讯作者：
Kusek, JW
影响因子：
6.6
作者：
Pontari, Michel A.;Joyce, Geoffrey F.;McNaughton-Collins, Mary
通讯作者：
McNaughton-Collins, Mary
影响因子：
2.1
作者：
Rosen, RC;Riley, A;Mishra, A
通讯作者：
Mishra, A
影响因子：
7.4
作者：
MELZACK, R
通讯作者：
MELZACK, R
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG